135 related articles for article (PubMed ID: 7480927)
1. [A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis].
Oliveira MR; Marsden PD
Rev Soc Bras Med Trop; 1995; 28(3):287. PubMed ID: 7480927
[No Abstract] [Full Text] [Related]
2. [A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
Oliveira MC; Amorim RF; Freitas Rde A; Costa Ade L
Rev Soc Bras Med Trop; 2005; 38(3):258-60. PubMed ID: 15895180
[TBL] [Abstract][Full Text] [Related]
3. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials.
Veiga JP; Wolff ER; Sampaio RN; Marsden PD
Lancet; 1983 Sep; 2(8349):569. PubMed ID: 6136717
[No Abstract] [Full Text] [Related]
4. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
[No Abstract] [Full Text] [Related]
5. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
Castro C; Sampaio RN; Marsden PD
Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
[No Abstract] [Full Text] [Related]
6. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
[TBL] [Abstract][Full Text] [Related]
7. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
8. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
10. [Meglumine antimoniate].
Silva JB
Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
[No Abstract] [Full Text] [Related]
11. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
12. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
13. [Symptomatic hypokalemia caused by meglumine antimoniate].
Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
[No Abstract] [Full Text] [Related]
14. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD
Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887
[TBL] [Abstract][Full Text] [Related]
15. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case].
Cucé LC; Belda Júnior W; Dias MC
Rev Inst Med Trop Sao Paulo; 1990; 32(4):249-51. PubMed ID: 2101518
[TBL] [Abstract][Full Text] [Related]
16. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
17. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
Lambertucci JR; França BM; Queiroz Ede M
Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
[No Abstract] [Full Text] [Related]
18. Clinical characteristics of human Leishmania braziliensis braziliensis infections.
Llanos Cuentas EA; Cuba CC; Barreto AC; Marsden PD
Trans R Soc Trop Med Hyg; 1984; 78(6):845-6. PubMed ID: 6533860
[No Abstract] [Full Text] [Related]
19. Acute airway obstruction due to oedema of the larynx following antimony therapy in mucosal leishmaniasis.
Costa JM; Netto EM; Marsden PD
Rev Soc Bras Med Trop; 1986; 19(2):109. PubMed ID: 3432621
[No Abstract] [Full Text] [Related]
20. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
